Latest KemPharm Inc. Stories
CORALVILLE, Iowa, Dec.
KP415 is Designed as an Abuse-Deterrent, Controlled Release Prodrug of Methylphenidate for the Treatment of ADHD CORALVILLE, Iowa, Dec.
KemPharm's Intellectual Property Estate Now Includes Composition of Matter Patents for Two Ligand Activated Technology (LAT) Opioid Prodrugs - KP511 and KP201 CORALVILLE, Iowa, Sept.
KemPharm Joins CLADD in Support of Legislation from Health Canada to Encourage More Responsible Development and Administration of Prescription Opioids CORALVILLE, Iowa, Sept.
Studies to Investigate Ability of KP201 to Deter Abuse and Reduce Opioid-Induced Constipation CORALVILLE, Iowa, Sept.
CORALVILLE, Iowa, Aug.
Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs
Patent Protection for KP511 Extends KemPharm's Intellectual Property Estate for Leading Franchise of Abuse-Deterrent Opioid Medications CORALVILLE, Iowa, April 30, 2014 /PRNewswire/
Composition of Matter Patents Issued in Multiple Countries for KemPharm's Lead Abuse-Deterrent Hydrocodone Prodrug CORALVILLE, Iowa, March 4, 2014 /PRNewswire/ -- KemPharm, Inc., a
CORALVILLE, Iowa, Feb.
- totally perplexed and mixed up.